X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://endpts.com/lady-gaga-returns-in-a-new-nurtec-migraine-ad-for-pfizer/
https://www.fiercepharma.com/pharma/late-party-nice-finally-signs-pfizers-nurtec-treat-migraine-attacks
https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lillys-migraine-drug-fails-meet-main-goal-post-approval-study-2023-06-16/
https://endpts.com/nice-recommends-pfizer-migraine-drug-in-uk-with-restrictions/
https://www.pharmaceutical-technology.com/news/first-in-class-migraine-treatment-vydura-approved-for-nhs-scotland/
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-recalls-migraine-drug-over-packaging-issues-cpsc-2023-03-16/
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-biohaven-pharmaceuticals
https://www.prnewswire.com/news-releases/real-world-administrative-claims-analysis-demonstrates-that-almost-half-of-migraine-patients-discontinue-barbiturate-use-after-initiation-of-nurtec-odt-301615194.html
https://endpts.com/biohaven-touts-surge-in-nurtec-sales-ahead-of-pfizer-takeover/
https://www.prnewswire.com/news-releases/biohaven-presents-new-migraine-data-at-64th-annual-scientific-meeting-of-the-american-headache-society-including-first-of-its-kind-study-for-nurtec-odt-rimegepant-and-complete-phase-3-data-for-zavegepant-nasal-spray-301566294.html
https://www.ema.europa.eu/en/documents/overview/vydura-epar-medicine-overview_en.pdf
https://endpts.com/pfizer-and-biohaven-bring-rimegepant-to-europe-as-migraine-war-with-abbvie-heats-up/
https://www.prnewswire.com/news-releases/nurtec-rimegepant-lactation-clinical-study-published-in-breastfeeding-medicine-journal-301515386.html
https://www.prnewswire.com/news-releases/biohaven-and-pfizer-receive-positive-chmp-opinion-for-migraine-treatment-301490453.html
https://www.prnewswire.com/news-releases/biohaven-and-pfizer-announce-positive-topline-results-of-pivotal-trial-of-rimegepant-for-the-acute-treatment-of-migraine-in-china-and-south-korea-301481322.html
https://www.prnewswire.com/news-releases/nurtec-odt-when-taken-as-an-acute-treatment-for-migraine-reduces-monthly-migraine-days-expanded-data-from-long-term-treatment-published-in-cephalalgia-reports-301474512.html
https://www.prnewswire.com/news-releases/biohaven-announces-preliminary-4q2021-and-full-year-net-product-revenue-for-nurtec-odt-market-leading-novel-migraine-therapy-301455426.html
https://www.prnewswire.com/news-releases/nurtec-odt-approved-in-kuwait-for-acute-treatment-of-migraine-301426599.html
https://www.prnewswire.com/news-releases/biohaven-spotlights-nurtec-odt-rimegepant-the-only-dual-therapy-indicated-for-both-the-acute-and-preventive-treatment-of-migraine-at-the-2021-international-headache-society--european-headache-federation-joint-congress-301372169.html
https://endpts.com/fda-calls-out-kardashian-drug-promo-video-for-false-claims/
https://www.raps.org/news-and-articles/news-articles/2021/3/kardashians-nurtec-claims-garner-opdp-untitled-let
https://www.prnewswire.com/news-releases/biohavens-rimegepant-for-preventive-treatment-of-migraine-published-in-the-lancet-301193664.html
https://www.fiercepharma.com/marketing/biohaven-revs-up-migraine-med-nurtec-odt-nascar-sponsorship
https://www.prnewswire.com/news-releases/biohaven-presents-nurtec-rimegepant-clinical-and-pharmacoeconomic-data-at-the-american-headache-society-ahs-virtual-annual-scientific-meeting-301077291.html
https://www.prnewswire.com/news-releases/biohaven-showcases-clinical-and-pharmacoeconomic-data-for-nurtec-odt-rimegepant-with-25-presentations-on-the-2020-american-academy-of-neurology-aan-science-highlights-virtual-platform-301060552.html
https://www.fiercepharma.com/pharma/ny-postpones-opioid-bellwether-trial-as-novel-coronavirus-concerns-spread
https://icer-review.org/announcements/icer-releases-draft-evidence-report-on-acute-migraine-therapies/
https://www.drugdevelopment-technology.com/news/biohaven-migraine-trial-rimegepant/
https://www.biospace.com/article/biohaven-s-migraine-drug-shows-superiority-for-freedom-from-pain-in-phase-iii/
https://www.fiercepharma.com/marketing/biohaven-touts-oral-cgrp-data-moves-closer-to-regulatory-finish-line-and-maybe-m-a
https://in.reuters.com/article/us-health-headaches-cluster-migraine/studies-explore-treatments-to-prevent-cluster-headaches-quell-migraines-idINKCN1U52PB
https://www.prnewswire.com:443/news-releases/novel-therapy-for-acute-migraine-shows-promise-in-phase-3-clinical-trial-300882935.html
https://www.prnewswire.com/news-releases/biohaven-announces-late-breaking-oral-presentation-of-rimegepant-zydis-odt-phase-3-results-at-american-academy-of-neurology-aan-2019-annual-meeting-and-new-data-release-at-investor-event-300843373.html
https://www.prnewswire.com/news-releases/biohaven-announces-completion-of-pre-nda-meeting-with-fda-for-oral-cgrp-receptor-antagonist-rimegepant-300811442.html
https://www.fiercebiotech.com/biotech/after-rare-disease-failure-biohaven-pushes-gas-oral-migraine-drug
Market Place
Share 
